Asia-Pacific journal of clinical oncology最新文献_第8页

Molecular profile of gastric adenocarcinoma, relevant epidemiological factors – Systematic review and meta-analysis relating sex with Epstein-Barr virus and unstable microsatellites subtypes 胃腺癌的分子特征、相关流行病学因素——与EB病毒和不稳定微卫星亚型的性别相关的系统综述和荟萃分析。

IF 1.9 4区医学 Q3 Medicine

Asia-Pacific journal of clinical oncology

Pub Date : 2023-11-06 DOI: 10.1111/ajco.14032

Gabriel Oliveira dos Santos, Warley Abreu Nunes, Waldemir Ferrari Júnior, Luiza Gomes Botega, Adriana Vial Roehe

Introduction

Gastric epithelial tumors exhibit morphological heterogeneity, diverse biological behaviors, and different oncopathological pathways. The Cancer Genome Atlas (TCGA) proposed a molecular classification of gastric adenocarcinomas based on genetic and molecular findings, which shows particular characteristics of diagnosis, prognosis, and indirectly, therapeutic alternatives. Within this classification, Epstein-Barr virus-positive (EBV+) and high microsatellite instability (MSI-H) subtypes stand out as subtypes that present a less aggressive biological behavior and a highly mutilated phenotype. This study conducted a systematic review with an emphasis on epidemiological and prognostic factors based on the molecular classification proposed by TCGA.

Methods

A broad, comprehensive, and reproducible search with methodological rigor was conducted for study selection using the ROBINS-I and GRADEpro protocols and appropriate combinations of keywords.

Results

A total of 25 studies were selected: six with a complete classification similar to TCGA and 19 with a distinction between MSI-H and EBV+. The application of meta-analysis calculations reinforces the prevalence of positive Epstein-Barr adenocarcinomas in males and high microsatellite instability in females, with a high level of certainty of evidence and low risk of bias in the analyzed studies due to the rigorous methods used.

Conclusion

The molecular classification proposed by TCGA shows limited dissemination, with MSI-H and EBV+ subtypes being the most researched, probably due to the benefit of the association with immunotherapies. However, the subclassification cannot be restricted to less than a quarter of the cases, and improvements in this aspect are urgent for the construction of knowledge on this important topic of global health.

引言：胃上皮肿瘤表现出形态异质性、不同的生物学行为和不同的肿瘤病理途径。癌症基因组图谱（TCGA）根据遗传和分子发现提出了胃腺癌的分子分类，显示了诊断、预后和间接治疗替代方案的特殊特征。在这一分类中，EB病毒阳性（EBV+）和高微卫星不稳定性（MSI-H）亚型是表现出较低攻击性生物学行为和高度残缺表型的亚型。本研究基于TCGA提出的分子分类，对流行病学和预后因素进行了系统综述。方法：使用ROBINS-I和GRADEpro方案以及适当的关键词组合，对研究选择进行了广泛、全面和可重复的方法学严谨搜索。结果：共选择了25项研究：6项具有类似TCGA的完整分类，19项具有MSI-H和EBV+之间的区别。荟萃分析计算的应用加强了男性Epstein-Barr腺癌阳性的患病率和女性微卫星高度不稳定的患病率，由于使用了严格的方法，在分析的研究中证据的确定性很高，偏倚的风险很低。结论：TCGA提出的分子分类显示出有限的传播性，MSI-H和EBV+亚型是研究最多的，这可能是由于与免疫治疗相关的益处。然而，分类不能局限于不到四分之一的病例，这方面的改进对于构建关于全球卫生这一重要主题的知识来说是迫切的。

{"title":"Molecular profile of gastric adenocarcinoma, relevant epidemiological factors – Systematic review and meta-analysis relating sex with Epstein-Barr virus and unstable microsatellites subtypes","authors":"Gabriel Oliveira dos Santos, Warley Abreu Nunes, Waldemir Ferrari Júnior, Luiza Gomes Botega, Adriana Vial Roehe","doi":"10.1111/ajco.14032","DOIUrl":"10.1111/ajco.14032","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Introduction</h3>\u0000 \u0000 Gastric epithelial tumors exhibit morphological heterogeneity, diverse biological behaviors, and different oncopathological pathways. The Cancer Genome Atlas (TCGA) proposed a molecular classification of gastric adenocarcinomas based on genetic and molecular findings, which shows particular characteristics of diagnosis, prognosis, and indirectly, therapeutic alternatives. Within this classification, Epstein-Barr virus-positive (EBV+) and high microsatellite instability (MSI-H) subtypes stand out as subtypes that present a less aggressive biological behavior and a highly mutilated phenotype. This study conducted a systematic review with an emphasis on epidemiological and prognostic factors based on the molecular classification proposed by TCGA.\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 A broad, comprehensive, and reproducible search with methodological rigor was conducted for study selection using the ROBINS-I and GRADEpro protocols and appropriate combinations of keywords.\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 A total of 25 studies were selected: six with a complete classification similar to TCGA and 19 with a distinction between MSI-H and EBV+. The application of meta-analysis calculations reinforces the prevalence of positive Epstein-Barr adenocarcinomas in males and high microsatellite instability in females, with a high level of certainty of evidence and low risk of bias in the analyzed studies due to the rigorous methods used.\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 The molecular classification proposed by TCGA shows limited dissemination, with MSI-H and EBV+ subtypes being the most researched, probably due to the benefit of the association with immunotherapies. However, the subclassification cannot be restricted to less than a quarter of the cases, and improvements in this aspect are urgent for the construction of knowledge on this important topic of global health.\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-11-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"71477500","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non-squamous non-small cell lung cancer after bevacizumab treatment 实体瘤的改良反应评估标准：贝伐单抗治疗后非鳞状非小细胞肺癌癌症患者的更好反应评估标准。

IF 1.9 4区医学 Q3 Medicine

Asia-Pacific journal of clinical oncology

Pub Date : 2023-10-29 DOI: 10.1111/ajco.14014

Yubao Huang, Yunkai Yang, Aidong Qu, Sixiu Li, Dandan Chen, Hongxia Zou, Songsong Li, Yaowen Zhang, Wei Zhuang, Jing Su, Xu Zhou, Yuntao Zhang

Aim

Cavitation of lesions is common in non-squamous non-small cell lung cancer (non-squamous-NSCLC) patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFRIs). However, traditional response evaluation criteria in solid tumors (RECIST) do not take cavitation into consideration and may no longer be accurate for potentially reflecting the real clinical efficacy of anti-vessel growth therapy. Here, we aimed to optimize the traditional RECIST version 1.1 by adding cavitation into the evaluation criteria.

Methods

We performed a post-hoc radiologic review of 517 patients in a phase III clinical trial of bevacizumab biosimilar (SIBP04) combined with chemotherapy for the treatment of non-squamous NSCLC. Tumor responses were assessed by RECIST1.1 and mRECIST criteria (modified RECIST, a novel alternate method where the longest diameter of the cavity was subtracted from the overall longest diameter of that lesion to measure target lesions), respectively, and correlated with clinical outcomes.

Results

Cavitations of pulmonary lesions were seen in nine (2%) patients at baseline, and 97 (19%) during treatment. The use of mRECIST resulted in an alteration of the response category. For patients with post-therapy cavitation, the objective response rate was 56% using RECIST1.1 and 67% by mRECIST. In addition, the survival rates between partial response, stable disease, and progressive disease when the mRECIST was applied were significantly different (p < 0.05), while RECIST1.1 failed to show survival differences (p = 0.218).

Conclusion

For patients with post-therapy cavitation, mRECIST exhibited higher predictability of survival than RECIST1.1. Response assessment might be improved by incorporating cavitation into assessment, potentially altering outcomes of key clinical efficacy parameters.

目的：血管内皮生长因子受体酪氨酸激酶抑制剂（VEGFRI）治疗的非鳞状非小细胞肺癌非鳞状-NSCLC）患者中，病灶空洞化是常见的。然而，传统的实体瘤反应评估标准（RECIST）没有考虑空化，可能不再准确地反映抗血管生长疗法的真实临床疗效。在这里，我们旨在通过在评估标准中添加空化来优化传统的RECIST 1.1版本。方法：在贝伐单抗生物类似物（SIBP04）联合化疗治疗非鳞状NSCLC的III期临床试验中，我们对517名患者进行了一项事后放射学审查。肿瘤反应分别通过RECIST1.1和mRECIST标准（改良的RECIST，一种新的替代方法，从病变的总最长直径中减去空腔的最长直径，以测量目标病变）进行评估，并与临床结果相关。结果：基线时有9例（2%）患者出现肺部空洞，治疗期间有97例（19%）患者出现。mRECIST的使用导致了响应类别的更改。对于治疗后出现气穴的患者，RECIST1.1的客观有效率为56%，mRECIST的客观有率为67%。此外，当应用mRECIST时，部分缓解、稳定疾病和进行性疾病的生存率存在显著差异（p结论：对于治疗后出现气穴的患者，mRECIST表现出比RECIST1.1更高的生存可预测性。反应评估可以通过将空化纳入评估来改进，这可能会改变关键临床疗效参数的结果。

{"title":"Modified response evaluation criteria in solid tumors: A better response evaluation criteria for patients with non-squamous non-small cell lung cancer after bevacizumab treatment","authors":"Yubao Huang, Yunkai Yang, Aidong Qu, Sixiu Li, Dandan Chen, Hongxia Zou, Songsong Li, Yaowen Zhang, Wei Zhuang, Jing Su, Xu Zhou, Yuntao Zhang","doi":"10.1111/ajco.14014","DOIUrl":"10.1111/ajco.14014","url":null,"abstract":"<div>\u0000 \u0000 \u0000 <section>\u0000 \u0000 <h3> Aim</h3>\u0000 \u0000 Cavitation of lesions is common in non-squamous non-small cell lung cancer (non-squamous-NSCLC) patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFRIs). However, traditional response evaluation criteria in solid tumors (RECIST) do not take cavitation into consideration and may no longer be accurate for potentially reflecting the real clinical efficacy of anti-vessel growth therapy. Here, we aimed to optimize the traditional RECIST version 1.1 by adding cavitation into the evaluation criteria.\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Methods</h3>\u0000 \u0000 We performed a post-hoc radiologic review of 517 patients in a phase III clinical trial of bevacizumab biosimilar (SIBP04) combined with chemotherapy for the treatment of non-squamous NSCLC. Tumor responses were assessed by RECIST1.1 and mRECIST criteria (modified RECIST, a novel alternate method where the longest diameter of the cavity was subtracted from the overall longest diameter of that lesion to measure target lesions), respectively, and correlated with clinical outcomes.\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Results</h3>\u0000 \u0000 Cavitations of pulmonary lesions were seen in nine (2%) patients at baseline, and 97 (19%) during treatment. The use of mRECIST resulted in an alteration of the response category. For patients with post-therapy cavitation, the objective response rate was 56% using RECIST1.1 and 67% by mRECIST. In addition, the survival rates between partial response, stable disease, and progressive disease when the mRECIST was applied were significantly different (p < 0.05), while RECIST1.1 failed to show survival differences (p = 0.218).\u0000 </section>\u0000 \u0000 <section>\u0000 \u0000 <h3> Conclusion</h3>\u0000 \u0000 For patients with post-therapy cavitation, mRECIST exhibited higher predictability of survival than RECIST1.1. Response assessment might be improved by incorporating cavitation into assessment, potentially altering outcomes of key clinical efficacy parameters.\u0000 </section>\u0000 </div>","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66783522","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retraction: LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1 回缩：LINC01133通过调节miR-30a-5p/FOXD1促进宫颈癌症的进展。

IF 1.9 4区医学 Q3 Medicine

Asia-Pacific journal of clinical oncology

Pub Date : 2023-10-27 DOI: 10.1111/ajco.13997

Retraction: Zhang D, Zhang Y, Sun X. LINC01133 promotes the progression of cervical cancer via regulating miR-30a-5p/FOXD1. Asia-Pac J Clin Oncol. 2021;17:253-263. https://doi.org/10.1111/ajco.13451. The above article, published online on 20 October 2020 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal's Editors-in-Chief, Professor Stephen Ackland and Professor Mengzhao Wang, and John Wiley & Sons Australia, Ltd. Following publication, concerns were raised by third parties regarding possible image duplication within Figures 2, 4 and 6. Upon investigation by the editorial team, it was concluded that several image elements of the experimental data were duplicated within figures in the article, or had already been published elsewhere in a different scientific context. Thus, the editors consider the conclusions of this article to no longer be reliable.

撤稿:张丹，张颖，孙鑫。LINC01133通过调控miR-30a-5p/FOXD1促进宫颈癌的进展。中华临床医学杂志，2011;17(2):563 - 563。https://doi.org/10.1111/ajco.13451。上述文章于2020年10月20日在线发表在Wiley在线图书馆(wileyonlinelibrary.com)上，经该杂志主编Stephen Ackland教授和Mengzhao Wang教授以及John Wiley & Sons Australia, Ltd.同意撤回。出版后，第三方对图2、图4和图6中可能出现的图像重复表示关注。经过编辑团队的调查，得出的结论是，实验数据的几个图像元素在文章中的数字中重复，或者已经在其他地方发表在不同的科学背景下。因此，编辑认为本文的结论不再可靠。

引用次数: 0

Author Listing 作者列表

IF 1.9 4区医学 Q3 Medicine

Asia-Pacific journal of clinical oncology

Pub Date : 2023-10-26 DOI: 10.1111/ajco.14027

Abo, S 237,59

Abousamra, A 433

Ackerman, I 253

Ackland, T 53

Adam, T 358

Adams, C 139

Adams, D 377

Adams, G 233

Adams, J 254

Adams, K 188

Adderley, H 42

Adlard, KN 198

Aga, A 189

Agar, M 164,356,433,434,450,451,452,514

Agar, MR 497

Ahern, E 305,306

Ahmadi, N 170,170,171,171

Ahmed, E 243

Ahn, M 199

Aitken, J 104,50

Aitken, JF 501

Akechi, T 491

Akhurst, T 515

Al Deleemy, M 219

Al-Mufti, T 300,318

Alamgeer, M 221

Alexander, H 314

Alexander, M 129,131,132

ALHulais, R 172

Allan, C 419

Allan, R 427

Allard, N 411

Allen, C 423

Allen, M 516

Allen, S 173

Alonso, M 200

Alsaid, H 78

Aly, A 180,187

Amgarth-Duff, I 450,497,514

Amil, A 415

Ananda, S 189

Anazodo, A 483

Andersen, S 407

Anderson, D 513

Anderson, H 288

Anderson, LE 160

Anderson, M 302

Anderson, W 30

Andree-Evarts, D 163,421,423

Andrew, C 449

Andrews, J 82

Angioli, R 174

Antill, YC 82

Antony, J 277

Arance, A 209

Aranda, S 83

Arendse, M 302

Arif, S 388

Ariyarathna, D 173

Arkadieff, K 416

Arneil, M 212

Arnolda, G 374

Arora, S 61

Arrington, D 263

Arulananda, S 178

Asadi, K 189

Ascierto, PA 209

Ashford, B 482

Ashwell, C 463

Ashwell, W 273

Aslam, M 301

Athan, S 128,129

Atkinson, V 212

Au-Yeung, G 117,364

Auchettl, J 412

Austen, M 93

Austin, E 373

Avery, S 194,370

Aye, P 302

Ayre, S 320

Ayub, Z 42

Aziez, A 78

Bagga, R 161

Bailey, E 74

Bailey, H 182

Bairstow, P 189

Baker, S 292

Baksa, S 429

Balaam, S 513

Balabhadrapatruni, C 78

Balachander, S 79

Balana, C 200

Baldwin, C 207

Ball, D 211

Ballinger, M 402

Bamgboje-Ayodele, A 277

Banerjee, A 174,78

Bang, A 23

Banks, E 52

Bansal, S 233

Baramidze, A 503

Bardia, A 248

Bareham, M 440,476

Barker, S 22

Barnes, J 302

Barnes, T 251

Barnett, F 333,395

Baron, A 216

Baron-Hay, S 196

Barratt, A 258

Barrios, C 248

Barry, JA 78

Bartle, J 510

Bartlett, S 281

Bartley, N 321,390

Barton, C 284

Barton, M 481,59

Bartula, I 424

Bastick, P 184

Bauer, J 208

Bauer, JD 164,239

Bauerschlag, D 174

Baxi, S 490

Baxter, K 412

Bayes, S 369

Beale, GK 175

Beaton, S 441

Beaton, SS 442

Beattie, A 136

Beatty, L 134,166,261,277,312,383,445,467,473

Beaven, C 176,177

Bechelli, M 178

Bejjani, C 433

Bekaii-Saab, T 101

Bell, K 164,243

Bell, R 133

Bellmunt, J 241

Benge, S 513

Bennett, G

Abo，S 237,59Abousamra，A 433Ackerman，I 253Ackland，T 53Adam，T 358Adams，C 139Adams，D 377Adams，G 233Adams，J 254Adams，K 188 Adderley，H 42Adlard，KN 198Aga，A 189Agar，M 164356433434450451452514gar，MR 497Ahern，E 305306Ahmadi，N 170170171171Ahmed，E 243Ahn，M 199Aitken，J 104,50Aitken，JF 501Akechi，T 491Akhurst，T 515Al Deleemy，M 219Al Mufti，T 300318 Alamgeer，M 221亚历山大，H 314Alexander，M 129131132AL Hulais，R 172Allan，C 419Allan，R 427Allard，N 411Allen，C 423Allen，M 516Allen，S 173Alonso，M 200Alsaid，H 78Aly，A 180187 Amgarth Duff，I 450497514mil，A 415Ananda，S 189Anazodo，A 483Andersen，S 407Anderson，D 513Anderson，H 288Anderson，LE 160Anderson，M 302Anderson，W 30Andree Evarts，D 163421423Andrew，C 449Andrews，J 82Angoli，R 174Antill，YC 82Antony，J 277Arance，A 209Aranda，S 83Arendse，M 302Arif，S 388Ariyarathna，D 173Arkadieff，K 416Arneil，M 212Arnolda，G 374Arora，S 61Arrington，D 263Arulananda，S 178Asadi，K 189Ascierto，PA 209Ashford，B 482Ashwell，C 463Ashwell，W 273Aslam，M 301Athan，S 128129Atkinson，V 212Au Yeung，G 117364Auchettl，J 412Austen，M 93Austin，E 373Avery，S 194370Aye，P 302Ayre，S 320Ayub，Z 42Ayub阿齐兹，A 78Bagga，R 161 Bailey，E 74 Bailey，H 182 Bairstow，P 189 Baker，S 292 Baksa，S 429Balaam，S 513 Balabhadrapatruni，C 78Balachander，S 79Balana，C 200 Baldwin，C 207 Ball，D 211 Ballinger，M 402Bamgboje Ayodele，A 277 Banerjee，A 174,78Bang，A 23Banks，E 52Bansal，S 233Baramidze，A 503Bardia，A 248Bareham，M 440476Barker，S 22Barnes，J 302Barnes，T 251Barnett，F 333395Baron，A 216Baron Hay，S 196Barratt，A 258Barrios，C 248Barry，JA 78Bartle，J 510Bartlett，S 281Bartley，N 321390Barton，C 284Barton，M 481,59Bartula，I 424Bastick，P 184Bauer，J 208Bauer，JD 164239Bauerschlag，D 174Baxi，S 490Baxter，K 412Bayes，S 369Beale，GK 175Beaton，S 441Beaton，SS 442Beattie，A 136Beatty，L 134166261277312383445467473Bechelli，M 178Bejjani，C 433Bekaii Saab，T 101Bell，K 164243Bell、R 133Bellmunt、J 241Benge、S 513Bennett、G 240242Bennett，I 305Bennett；KF 272Benson、W 78Benzaghou、F 101Bergin、R 501Berrett、J 352Berry、M 243Best、S 322352353372Bettington、C 314Bhandari、A 412Bhasker、S 165205235508Bhattacharya、A 179Bhattacharyya、S 161Bhimani、N 169Bigaran、A 180187453502 Black、A 186 Black、D 174Black Tiong、S 323Blackberry，I 254276460489 Blackmore，T 432Blake，C 406407Blakely，B 373Blanchard，G 281Bland，K 502Blinman，P 238450Bloomquist，K 37,39,40Bloomqui斯特，KK 41Blum，R 189Blyth，F 52Bochynska，K 443444Body，A 306Boltong，A 93Bone，A 113Boolell，V 247Booth，R 281Bornman，R 203Bossi，P 233Bourke，J 484Boussioutas，A 189Bowden，J 439Bowden，N 215511Bowen，J 447Bowman，A 324325Bowtell，D 193515,7 9Bowyer，S 221 Bowyer，SS 308Boyle，F 290384397477 Boytar，A 198 Boytar，AN 84 Bradford，A 10237471,57Bradford，N 365396420 Brady，B 230 Brain，E 33 Braithwaite，J 374Brancato，J 93 Brand，G 262 Brand，M 404 Bray，S 471Bray，V 195243358Brazzale，D 180187Brennan，L 206Brennen，R 269270271448Brenner，D 8,94Bressel，M 221Brims，F 214,60,99Briscoe，K 221Britto，J 283Brkic，E 445Broadbent，S 459496Brook，N 454 Brosnan，K 422 Brotherton，J 47Brown，A 173 Brown，C 251 Brown，L 433434497514 Brown，M 301Brown，S 189,52 Brown，T 182239406407 Br

{"title":"Author Listing","authors":"","doi":"10.1111/ajco.14027","DOIUrl":"https://doi.org/10.1111/ajco.14027","url":null,"abstract":"Abo, S 237,59Abousamra, A 433Ackerman, I 253Ackland, T 53Adam, T 358Adams, C 139Adams, D 377Adams, G 233Adams, J 254Adams, K 188Adderley, H 42Adlard, KN 198Aga, A 189Agar, M 164,356,433,434,450,451,452,514Agar, MR 497Ahern, E 305,306Ahmadi, N 170,170,171,171Ahmed, E 243Ahn, M 199Aitken, J 104,50Aitken, JF 501Akechi, T 491Akhurst, T 515Al Deleemy, M 219Al-Mufti, T 300,318Alamgeer, M 221Alexander, H 314Alexander, M 129,131,132ALHulais, R 172Allan, C 419Allan, R 427Allard, N 411Allen, C 423Allen, M 516Allen, S 173Alonso, M 200Alsaid, H 78Aly, A 180,187Amgarth-Duff, I 450,497,514Amil, A 415Ananda, S 189Anazodo, A 483Andersen, S 407Anderson, D 513Anderson, H 288Anderson, LE 160Anderson, M 302Anderson, W 30Andree-Evarts, D 163,421,423Andrew, C 449Andrews, J 82Angioli, R 174Antill, YC 82Antony, J 277Arance, A 209Aranda, S 83Arendse, M 302Arif, S 388Ariyarathna, D 173Arkadieff, K 416Arneil, M 212Arnolda, G 374Arora, S 61Arrington, D 263Arulananda, S 178Asadi, K 189Ascierto, PA 209Ashford, B 482Ashwell, C 463Ashwell, W 273Aslam, M 301Athan, S 128,129Atkinson, V 212Au-Yeung, G 117,364Auchettl, J 412Austen, M 93Austin, E 373Avery, S 194,370Aye, P 302Ayre, S 320Ayub, Z 42Aziez, A 78Bagga, R 161Bailey, E 74Bailey, H 182Bairstow, P 189Baker, S 292Baksa, S 429Balaam, S 513Balabhadrapatruni, C 78Balachander, S 79Balana, C 200Baldwin, C 207Ball, D 211Ballinger, M 402Bamgboje-Ayodele, A 277Banerjee, A 174,78Bang, A 23Banks, E 52Bansal, S 233Baramidze, A 503Bardia, A 248Bareham, M 440,476Barker, S 22Barnes, J 302Barnes, T 251Barnett, F 333,395Baron, A 216Baron-Hay, S 196Barratt, A 258Barrios, C 248Barry, JA 78Bartle, J 510Bartlett, S 281Bartley, N 321,390Barton, C 284Barton, M 481,59Bartula, I 424Bastick, P 184Bauer, J 208Bauer, JD 164,239Bauerschlag, D 174Baxi, S 490Baxter, K 412Bayes, S 369Beale, GK 175Beaton, S 441Beaton, SS 442Beattie, A 136Beatty, L 134,166,261,277,312,383,445,467,473Beaven, C 176,177Bechelli, M 178Bejjani, C 433Bekaii-Saab, T 101Bell, K 164,243Bell, R 133Bellmunt, J 241Benge, S 513Bennett, G ","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14027","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68180156","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Poster Listing 海报列表。

IF 1.9 4区医学 Q3 Medicine

Asia-Pacific journal of clinical oncology

Pub Date : 2023-10-26 DOI: 10.1111/ajco.14024

Leah Zajdlewicz

Decisions and prompts to screen for cervical, bowel, and breast cancer abs# 160

Shalmoli Bhattacharyya

Cancer-associated mesenchymal stem cells promote proliferation in chemo-radio-resistant cervical cancer cells abs# 161

Carina Chan

Identifying MET exon 14 skipping mutations in squamous cell lung cancer patients abs# 162

Zoe Clarke

Medical imaging simulated radiation therapy: Improving access to palliative radiation therapy in WNSWLHD abs# 163

Merran Findlay

Dashboards to deliver data-driven dietetics in the digital age: Translation of evidence-based nutrition guidelines into practice abs# 164

Subhash Gupta

Emerging therapeutic potential of Vardhamana Pippali Rasayana (Ayurvedic drug) in breast cancer abs# 165

Morgan Leske

Feasibility and preliminary efficacy of brief coaching calls in Healthy Living after Cancer Online: A randomized control trial abs# 166

Ashley Macleod

Investigating LGBTIQA+ Inclusion in Victorian Cancer Care: An incomplete picture abs# 167

Georgios Mavropalias

Implementation of eccentric exercise programs as therapy during cancer – A scoping review abs# 168

Geoffrey Yuet Mun Wong

Genomic profiling and biomarker discovery for predicting early intrahepatic recurrence following resection of colorectal liver metastases abs# 169

Navid Ahmadi

Perioperative and oncological outcomes of patients undergoing post-chemotherapy robotic-retroperitoneal lymph node dissection for management of primary testicular cancer abs# 170

Navid Ahmadi

Perioperative and oncological outcomes of patients undergoing primary robotic-RPLND for management of primary testicular cancer abs# 171

Reem ALHulais

Efficacy of celecoxib as an anticancer drug examined in the murine CT26 metastatic colorectal cancer model abs# 172

Dinuka Ariyarathna

Providing early access to geriatric oncology services in a regional cancer center – An evaluation of a newly established Nurse-Navigator led Geriatric Oncology Service Model and associated safety outcomes abs# 173

Ashish Banerjee

Dostarlimab for Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): Outcomes by Blinded Independent Central Review (BICR) of the RUBY trial abs# 174

Greta K Beale

Association between clinical outcomes and PSMA PET metrics in patients with metastatic prostate cancer abs# 175

Cassie Beaven

Immunotherapy in the setting of metastatic cutaneous squamous cell carcinoma – An OncoGeriatrics Perspective abs# 176

Cassie Beaven

An evaluation of time to treatment with adjuvant chemotherapy in high-risk early breast cancer patients in a r

Leah Zajdlewicz决定和提示筛查宫颈、肠道、，和癌症abs#160Shalmoli BhattacharyyaCancer-associated间充质干细胞促进化疗耐药宫颈癌症细胞的增殖abs#161Carina Chan识别鳞状细胞肺癌癌症患者的MET外显子14跳跃突变abs#162 Zoe Clarke医学成像模拟放射治疗：改善WNSWLHD患者接受姑息性放射治疗的机会abs#163Merran FindlayDashboards在数字时代提供数据驱动的营养学：将循证营养指南转化为实践abs#164 Subhash Gupta Vardhamana Pippali Rasayana（阿育吠陀药物）在乳腺癌症中的治疗潜力abs#165 Morgan Leske癌症后健康生活中简短辅导电话的可行性和初步效果在线：随机对照试验abs#166Ashley MacleodInvestigating LGBTIQA+Inclusion in Victorian癌症护理：一张不完整的照片abs#167Georgios Mavropalias在癌症期间实施偏心运动计划作为治疗——范围审查abs#168 Geoffrey Yuet-Mun Wong预测结直肠癌切除后早期肝内复发的基因组分析和生物标志物发现转移abs#169Navid Ahmadi接受化疗后机器人-腹腔淋巴结清扫治疗原发性睾丸癌症的患者的围手术期和肿瘤结果abs#170Navid Ahmedi接受原发性机器人-RPLND治疗原发期睾丸癌症的患者的术中和肿瘤结果abs#171Reem ALHulais塞来昔布作为一种在小鼠CT26转移性结直肠癌癌症模型中检查的抗癌药物abs#172Dinuka Ariyarathna在癌症地区中心提供早期老年肿瘤服务——对新建立的Nurse-Navigator领导的老年肿瘤服务模型和相关安全性结果的评估abs#173Ashish Banerjee Dostarlimab用于原发性晚期或复发（a/R）子宫内膜癌症（EC）：RUBY试验盲独立中心审查（BICR）的结果abs#174Greta K Beale转移性前列腺癌症患者的临床结果和PSMA PET指标之间的关联abs#175Cassie Beaven转移性皮肤鳞状细胞癌背景下的免疫治疗——肿瘤老年医学视角abs#176Cassie Beane时间评估在区域环境中对高危早期癌症乳腺癌患者进行辅助化疗abs#177Maria Bechelli改善试验的机会：一种用于识别招募患者的快速病例确定工具abs#178Anish Bhattacharya 18F-FDG PET/CT在小儿肉瘤的初始分期和治疗计划中的作用abs#179 Jaimee CaciPrehabilitation改善食管-胃癌症手术前的营养和肌肉参数abs#180Cian病例PET/CT经皮活检对可疑腹膜后肉瘤的诊断功效abs#181 Felicity病例Real-world疾病特征、测试模式、，澳大利亚RET融合阳性晚期非小细胞肺癌癌症的一线治疗abs#182David Chen接受胆道切除术的肿瘤患者围手术期因素与DAH30之间的关联：一项回顾性队列研究abs#183Kar Ven Cavan ChowReal-world颅外结果和实践，性腺外生殖细胞肿瘤：澳大利亚iTestis数据库的回顾性分析abs#184Udari Colombage盆底肌肉训练治疗癌症妇女尿失禁的可行性：远程健康干预试验abs#185Jermaine Coward AdvanTIG-105:检查点抑制剂（CPI）患者中ociperlimab+tislelizumab的1b期剂量扩展研究-经历过晚期非小细胞肺癌癌症（NSCLC）abs#186Kate Crombie康复减少了食管胃癌症手术后的术后并发症abs#187Letta D’Costa什么是“真正的种族主义”——医护人员对种族和种族主义的认知abs#188Bianka D’souzaHER2在晚期癌症中的检测——了解并减少当前改善患者结果公平性的实践abs#189 Daphne DayA口服完全雌激素受体（ER）拮抗剂（CERAN）和选择性ER降解剂（SERD）OP-1250在晚期或转移性ER-阳性、HER2-阴性癌症（MBC）患者（pts）中的1b/2期研究abs#190 Daphne DayA OX40激动剂BGB-A445的1期（Ph1）研究，抗PD-1单克隆抗体（mAb），在晚期实体瘤患者中腹肌#191乔治亚·德安布罗斯一例脸颊原发性皮肤边缘区B细胞淋巴瘤腹肌#192克里斯汀·迪克斯特拉解决未知的原发性癌症（SUPER）：一项队列研究——数字化和适应挑战腹肌#193海莉·T·狄龙运动和久坐行为联合干预在接受手术的成年人中保留了VO2峰值

{"title":"Poster Listing","authors":"","doi":"10.1111/ajco.14024","DOIUrl":"10.1111/ajco.14024","url":null,"abstract":"Leah ZajdlewiczDecisions and prompts to screen for cervical, bowel, and breast cancer abs# 160Shalmoli BhattacharyyaCancer-associated mesenchymal stem cells promote proliferation in chemo-radio-resistant cervical cancer cells abs# 161Carina ChanIdentifying MET exon 14 skipping mutations in squamous cell lung cancer patients abs# 162Zoe ClarkeMedical imaging simulated radiation therapy: Improving access to palliative radiation therapy in WNSWLHD abs# 163Merran FindlayDashboards to deliver data-driven dietetics in the digital age: Translation of evidence-based nutrition guidelines into practice abs# 164Subhash GuptaEmerging therapeutic potential of Vardhamana Pippali Rasayana (Ayurvedic drug) in breast cancer abs# 165Morgan LeskeFeasibility and preliminary efficacy of brief coaching calls in Healthy Living after Cancer Online: A randomized control trial abs# 166Ashley MacleodInvestigating LGBTIQA+ Inclusion in Victorian Cancer Care: An incomplete picture abs# 167Georgios MavropaliasImplementation of eccentric exercise programs as therapy during cancer – A scoping review abs# 168Geoffrey Yuet Mun WongGenomic profiling and biomarker discovery for predicting early intrahepatic recurrence following resection of colorectal liver metastases abs# 169Navid AhmadiPerioperative and oncological outcomes of patients undergoing post-chemotherapy robotic-retroperitoneal lymph node dissection for management of primary testicular cancer abs# 170Navid AhmadiPerioperative and oncological outcomes of patients undergoing primary robotic-RPLND for management of primary testicular cancer abs# 171Reem ALHulaisEfficacy of celecoxib as an anticancer drug examined in the murine CT26 metastatic colorectal cancer model abs# 172Dinuka AriyarathnaProviding early access to geriatric oncology services in a regional cancer center – An evaluation of a newly established Nurse-Navigator led Geriatric Oncology Service Model and associated safety outcomes abs# 173Ashish BanerjeeDostarlimab for Primary Advanced or Recurrent (A/R) Endometrial Cancer (EC): Outcomes by Blinded Independent Central Review (BICR) of the RUBY trial abs# 174Greta K BealeAssociation between clinical outcomes and PSMA PET metrics in patients with metastatic prostate cancer abs# 175Cassie BeavenImmunotherapy in the setting of metastatic cutaneous squamous cell carcinoma – An OncoGeriatrics Perspective abs# 176Cassie BeavenAn evaluation of time to treatment with adjuvant chemotherapy in high-risk early breast cancer patients in a r","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14024","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

2023 COSA ASM Exhibitor Listing 2023 COSA ASM参展商名单。

IF 1.9 4区医学 Q3 Medicine

Asia-Pacific journal of clinical oncology

Pub Date : 2023-10-26 DOI: 10.1111/ajco.14029

引用次数: 0

Program in Detail 详细程序。

IF 1.9 4区医学 Q3 Medicine

Asia-Pacific journal of clinical oncology

Pub Date : 2023-10-26 DOI: 10.1111/ajco.14023

Empowering excellence: advancing the quality and safety of gynaecological cancer care in Queensland

Chair: Rhett Morton

7:00 AM Rhett Morton

Navigating the pathways: Patterns of care for all women with gynaecological cancer in Queensland abs# 1

7:15 AM Tamara Butler

Ensuring equity: Monitoring health outcomes for Queensland First Nations women with cervical and endometrial cancer abs# 2

7:30 AM Penny Mackenzie

Trends in the utilisation of brachytherapy in cervical cancer in Queensland: How do we compare? abs# 3

7:45 AM Shaun McGrath

Increased endometrial cancer rates: The link between obesity and endometrial cancer risk abs# 4

Session sponsored by

Innovations in Implementing Nutrition and Exercise Evidence to Enhance Cancer Care and Outcomes

Co-Chair: Jenelle Loeliger

Co-Chair: David Mizrahi

This session will include interactive Q&A with all speakers.

This breakfast session is sponsored by COSA, and delivered by the COSA Nutrition and Exercise and Cancer Groups

Best of the Best Posters – Epidemiology

Chair: Ashley Hopkins

Discussant: Rebecca Venchiarutti

7:15 AM Maria Aslam

Prevalence of Australians exposed to potentially cardiotoxic cancer medicines: A population-based cohort study abs# 301

7:20 AM Vicki Durston

Making metastatic breast cancer count: Barriers, enablers and key recommendations identified through expert interviews and a national roundtable abs# 304

7:25 AM Lucy Gately

Linking data from a brain cancer clinical registry (BRAIN) with the state-based registry of Births Deaths Marriages: Improving the quality of clinical registry survival data abs# 305

7:30 AM Huah Shin Ng

Patterns of mental health service utilisation in people with cancer compared with people without cancer: The Australian National Study of Mental Health and Wellbeing analysis abs# 312

7:35 AM Suzanne Poulgrain

Patterns of treatment and survival outcomes for people diagnosed with glioblastoma: A population-based study in Queensland abs# 314

7:40 AM Robert Power

Modifiable risk factors for cancer among people with Lynch syndrome: An international, cross-sectional survey abs# 315

7:45 AM Euan Walpole

Benchmarking statewide cancer data: A comparison of breast and gynaecological cancer care indicators between Victoria and Queensland abs# 316

Session sponsored by

Best of the Best Posters – Clinical Research & Supportive Care

Chair: Laura Kirsten

Discussant: Desmond Yip

7:15 AM Morgan Farley

abs#2711:15 AM Norah Finn与最佳护理途径的早期检测阶段相一致与改善癌症妇女的预后有关abs#2811:30 AM Caitlin I Fox-Harding乳腺癌相关淋巴水肿的高负荷与低负荷耐力运动：一项随机对照试验abs#2911:45 AM Yada Kanjanapa癌症患者的现实世界分析符合辅助CDK4/6抑制剂的资格abs#3012:00 PM Antonia Pearson癌症妇女的泌尿生殖系统症状：患者的态度和经历abs#3112:15 PM Kate Webber实时患者报告结果测量（PROM）对癌症乳腺癌患者急诊科表现的影响abs#32午餐由在老年肿瘤学中回答这些老年问题下午1:30 Etienne Brain研究癌症的人口统计学转变（国际和学术合作的想法）abs#331:50 PM Heather Lane老年肿瘤学：老年医生的作用abs#342:05 PM Michael Krasovitsky照顾癌症老年人：医学肿瘤学家的聚会abs#352:20 PM Polly Dufton护理和联合健康在护理患有癌症的老年人中的作用abs#362:35 PM小组讨论由癌症相关淋巴水肿赞助的会议：从预防到管理主席：Sandi Hayes4:00 PM Melanie Plinsinga淋巴水肿有多大问题？腹肌#337:17 PM Louise Koelmeyer预防淋巴水肿的探索腹肌#384:34 PM Hildegard Reul-Hiche减少淋巴水肿的影响：通过手术方法进行保守管理腹肌#394:51 PM Kira Bloomquist运动和体重管理对癌症相关淋巴水肿的影响腹肌#405:08 PM Debbie Geyer消除淋巴水肿管理中的神话腹肌#415:25 PM小组讨论医学问题主席：Chi Hao La4:00 PM Faye Coe先前治疗线的平均持续时间预测艾瑞布林化疗对转移性乳腺癌癌症患者的临床益处abs#424:20 PM Gail Rowan癌症中新出现的抗体药物偶联物abs#434:40 PM Peter Savas在乳腺癌中利用免疫系统abs#445:00 PMOlivia SmibertMedicines and the microbiome abs#45消除癌症宫颈癌战略：澳大利亚的成功故事激励全球行动主席：Marion Saville4:00 PM Karen Canfell澳大利亚和全球战略概述abs#464:15 PM Julia Brotherton提高疫苗接种和筛查率的实施策略？abs#474:30 PM Lisa Whop在土著和托雷斯海峡岛民社区实现消除宫颈癌症abs#484:45 PM Farhana SultanaHPV在澳大利亚的宫颈筛查：项目中的自我收集和随访abs#495:00 PM小组讨论最佳口头陈述-支持性护理主席：Belinda SteerDiscussant:Michael Jefford4:00PM Louisa Gordon原发性脑瘤患者远程健康心理支持干预的成本效益分析：远程健康对脑瘤的意义腹肌#504:15 PM Lauren Ha致力于更好地评估身体活动和久坐行为：一种使用腕关节加速度计对儿童癌症幸存者进行新的聚类分析方法腹肌#514:30 PM Bogda与癌症相关的KoczwaraPain及其对日常生活的干扰：对16053名癌症幸存者和106345名癌症未患者进行的基于人群的比较研究。澳大利亚维多利亚州吉普斯兰市农村癌症幸存者的财务毒性（abs#535:00 PM Eli Ristevski）abs#545:15 PM Eva YuenDoes护理人员和癌症患者的健康素养、社会支持和联系影响护理人员的心理发病率？abs#55最佳口头演讲-健康服务I主席：Wei-Sam LamDiscussant:Kim Hobbes4:00 PM Jennifer Cohere一项由父母主导的计划，旨在促进癌症后儿童的健康饮食习惯：一项随机对照试验。腹肌#564:15 PM Prue Cormie锻炼对话：一项混合方法研究，解释了健康专业人员需要将锻炼建议嵌入癌症常规护理腹肌#574:30 PM Suzanne Grant培训医疗口译员关于癌症临床试验腹肌#584:45 PM Ella Sexton和Hannah Ray利用共同设计的头部资源实施护理的康复模型正在接受放射治疗的癌症患者腹肌#595:00 PM Shalini VinodLung癌症（基于互联网）Delphi（LuCiD）：建立澳大拉西亚胸部肿瘤学临床质量指标的改良eDelphi共识腹肌#605:15 PM Haitham Tuffaha前列腺癌症基因检测共识建议：Delphi研究腹肌#61 COSA高级学员晚宴：关于如何治疗高危早期癌症的完整指南-从我们的专家那里获得多学科团队的观点主席：Belinda Yeo本次晚宴特别适合我们在癌症管理任何专业的受训人员。我们将听取关于如何治疗高危早期癌症的重要外科、整形、放射和医学肿瘤学观点。患者和临床医生面临的挑战是，要做出这些知情的决定，需要制定什么样的治疗、按照什么顺序以及什么样的成像和病理信息。我们期待着一个有趣的夜晚，与您在乳腺癌症护理相关学科的同事见面！这次会议由诺华公司资助。内容和议程由COSA和医学专家独立制定。癌症药剂师晚宴-走向药剂师处方：满足我们患者的需求Co-Chair：Marissa RyanCo-Chair:Kimberly-Ann Kerr癌症药剂师处方-我们正在接近吗？药剂师已经在积极为癌症患者在入院前、治疗和出院或过渡计划期间提供优质护理。临床药剂师的角色已经演变，药剂师在审查患者的药物相关问题后，为医疗团队提供有价值的建议。虽然在社区环境中有一些建议和试验举措，但澳大利亚的药剂师处方目前非常有限。相比之下，药剂师自2003年以来一直在英国开处方。他们是如何做到这一点的？我们能从英国的同事那里学到什么？药剂师处方医生面临哪些挑战？在本次研讨会上，我们将讨论英国模式、其运作方式以及澳大利亚正在进行的高级药剂师实践，包括合作药剂师药物图表（PPMC）。PPMC模式已在维多利亚州的普通医学和最近的肿瘤学环境中进行了测试和实施。在PPMC模式下，药剂师被置于一个独特的位置，可以审查、记录药物并与处方医生共同制定药物图表。PPMC是向药剂师处方和高级实践迈出的一步吗？这会成为药剂师开处方的依据吗？我们如何才能建立高级执业药剂师模式？由Fight with care赞助的会议-科学指南和合作伙伴关系，以改善因癌症治疗而产生皮肤毒性的患者的治疗机会主席：Victoria MarFight with care副教授是La Roche Posay的新项目，旨在强调在治疗肿瘤治疗副作用时采用整体方法的重要性。我们欢迎您与活动背后的科学专家一起参加我们的晚会，围绕肿瘤患者皮肤毒性的治疗指南和管理进行讨论，并了解我们与麦格拉斯基金会合作所做的工作，以推动因癌症治疗而出现皮肤毒性的患者更好地获得治疗。皮肤毒性与护理抗争计划启动，包括。亚历山大公主医院的肿瘤病科诊所由Age赞助的

{"title":"Program in Detail","authors":"","doi":"10.1111/ajco.14023","DOIUrl":"10.1111/ajco.14023","url":null,"abstract":"\u0000 \u0000 Empowering excellence: advancing the quality and safety of gynaecological cancer care in Queensland\u0000 \u0000 Chair: Rhett Morton7:00 AM Rhett MortonNavigating the pathways: Patterns of care for all women with gynaecological cancer in Queensland abs# 17:15 AM Tamara ButlerEnsuring equity: Monitoring health outcomes for Queensland First Nations women with cervical and endometrial cancer abs# 27:30 AM Penny MackenzieTrends in the utilisation of brachytherapy in cervical cancer in Queensland: How do we compare? abs# 37:45 AM Shaun McGrathIncreased endometrial cancer rates: The link between obesity and endometrial cancer risk abs# 4Session sponsored by\u0000 Innovations in Implementing Nutrition and Exercise Evidence to Enhance Cancer Care and Outcomes\u0000 \u0000 Co-Chair: Jenelle LoeligerCo-Chair: David MizrahiThis session will include interactive Q&A with all speakers.This breakfast session is sponsored by COSA, and delivered by the COSA Nutrition and Exercise and Cancer Groups Best of the Best Posters – Epidemiology\u0000 \u0000 Chair: Ashley HopkinsDiscussant: Rebecca Venchiarutti7:15 AM Maria AslamPrevalence of Australians exposed to potentially cardiotoxic cancer medicines: A population-based cohort study abs# 3017:20 AM Vicki DurstonMaking metastatic breast cancer count: Barriers, enablers and key recommendations identified through expert interviews and a national roundtable abs# 3047:25 AM Lucy GatelyLinking data from a brain cancer clinical registry (BRAIN) with the state-based registry of Births Deaths Marriages: Improving the quality of clinical registry survival data abs# 3057:30 AM Huah Shin NgPatterns of mental health service utilisation in people with cancer compared with people without cancer: The Australian National Study of Mental Health and Wellbeing analysis abs# 3127:35 AM Suzanne PoulgrainPatterns of treatment and survival outcomes for people diagnosed with glioblastoma: A population-based study in Queensland abs# 3147:40 AM Robert PowerModifiable risk factors for cancer among people with Lynch syndrome: An international, cross-sectional survey abs# 3157:45 AM Euan WalpoleBenchmarking statewide cancer data: A comparison of breast and gynaecological cancer care indicators between Victoria and Queensland abs# 316Session sponsored by Best of the Best Posters – Clinical Research & Supportive Care\u0000 \u0000 Chair: Laura KirstenDiscussant: Desmond Yip7:15 AM Morgan Farley</","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14023","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227517","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0

Poster Abstracts 海报摘要
IF 1.9 4区医学 Q3 Medicine
Asia-Pacific journal of clinical oncology
Pub Date : 2023-10-26 DOI: 10.1111/ajco.14026

Laura E Anderson^1,2, Katelyn Collins^1,3, Larry Myers^1,3, Michael J Ireland^3,4, Mariam Omar¹, Allanah Drummond³, Leah Zajdlewicz¹, Belinda Goodwin^1,4,5
¹Cancer Council Queensland, Fortitude Valley, Queensland, Australia
²National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Queensland, Australia
³School of Psychology and Wellbeing, University of Southern Queensland, Springfield, Queensland, Australia
⁴Centre for Health Research, University of Southern Queensland, Springfield, Queensland, Australia
⁵Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Queensland, Australia
Aims: Population-wide cancer screening programs save lives through early cancer detection; however, many people do not participate. We aimed to understand decision formation and prompts to action for screening behaviours to inform interventions to increase bowel, breast and cervical cancer screening uptake.
Methods: Cancer screeners (N = 962) were asked what made them decide to screen and what prompted them to act through an online survey. Content analysis was used to capture the frequency of common responses. Interrater reliability was high (κ = .96, %agree = 97%).
Results: For breast and cervical screening, decisions were commonly based on ‘screening being routine’ (32.58% – breast, 35.19% – cervical) or ‘receiving a reminder’ (20.53% – breast, 13.07% – cervical), and common prompts were ‘receiving a reminder’ (40.68% – breast, 29.13% – cervical), ‘screening being routine’ (22.05% breast, 18.65% cervical). Participants reported deciding to screen for bowel cancer due to ‘arrival of home screening test kit’ (40.50%) or the ‘experience of loved one's cancer’ (13.57%) and were prompted by ‘arrival of home test kit’ (23.58%), ‘convenience’ (15.72%) and the ‘desire to “get it over with”’ (10.22%). Importantly, approximately 25% of participants gave the same response to both the decision and prompt question.
Conclusions: Interventions should target reminders and messages that support screening as part of regular healthcare routine, particularly for breast and cervical cancer screening. For bowel cancer screening, messaging should encourage immediate use of bowel cancer screening kits upon arrival. The messaging inviting individuals to screening programs should be carefully considered, as it often coincides with both the decision to participate and prompts action.
Shalmoli Bhattacharyya¹, Sanchita Khurana¹, Reena Sharma², Bhavana Rai², Rashmi Bagga³
¹Biophysics, PGIMER, Chandigarh, India
²Radiotherapy, PGIMER, Chandi

方法：该多方法试点包括准实验性测试前/测试后设计和使用可接受性理论框架（TFA）的探索性定性研究。研究参与者包括：新诊断为局部前列腺癌症的男性，他们在前3个月内接受了根治性或机器人前列腺切除术；以及参与项目开发和/或交付的临床医生/利益相关者。该干预措施针对术后恢复过程量身定制，旨在通过视频会议在12周内进行症状管理、心理教育、问题解决和目标设定。这项研究的主要结果衡量标准是项目的可接受性。次要结果指标包括：生活质量、前列腺癌症相关痛苦、失眠严重程度、疲劳严重程度和项目成本。结果：男性（n=17）和服务利益相关者（n=6）在TFA的所有结构中都报告了非常高的项目可接受性水平。对于男性来说，与项目参与相关的微不足道的负担和机会成本，加上强烈的项目道德感，是坚持和感知项目有效性的关键驱动因素。在临床上，该计划改善了护理协调，加快了对生存护理需求的识别，并满足了在家附近提供优质护理的服务优先级，近一半（47%）的男性报告了临床上显著的心理困扰，在24周时显著减轻（p=0.020）。从基线到24周，尿刺激/阻塞症状显著改善（p=0.030），尿功能负担相应减轻（p=0.005）。从基线到24周，当前疲劳（p=0.024）和过去24小时内疲劳干扰生活的程度（p=0.041）显著增加，反映出与大手术相关的持续疲劳。结论：这项研究的结果表明，在区域环境中，通过视频会议提供的虚拟术后护理对癌症前列腺癌幸存者来说是高度可接受的。Martin Hong1，Rebecca Nguyen1，Tamiem Adam2，Po Yee Yip3，Victoria Bray1，Ina Nordman4，Fiona Day4，Hiren Mandaliya4，Abhijit Pal11利物浦医院，新南威尔士州利物浦，澳大利亚2医学肿瘤科，Bankstown医院，Bankstoown，NSW，Australia3坎贝尔镇医院，Campbelltown，NSW，澳大利亚背景：广泛期小细胞肺癌癌症（ES-SCLC）预后不良，使用铂和依托泊苷（EP）化疗的中位生存期为10个月。1 IMpower133显示，在铂和依托泊苷（EP+atezolizumab）化疗的基础上加用atezolizmab可适度改善无进展生存期（PFS）和总生存期（OS）由于随机临床试验中控制的现实世界患者的许多因素的异质性，临床试验并不等同于现实世界的实践。真实世界的实践提供了有关干预的有效性和安全性的进一步信息。3-5本研究旨在调查在澳大利亚四个中心接受治疗的真实世界患者的结果，以评估添加atezolizumab的疗效。方法：我们回顾性分析了2018年至2021年间接受系统治疗的ES-SCLC患者。主要终点为OS，次要终点为PFS。使用描述性统计分析基线特征。OS和PFS使用Kaplan–Meier方法进行评估，风险比（HR）使用Cox比例风险方法计算。结果：2018年至2021年间，共有156名ES-SCLC患者在我们的中心接受了治疗。EP的中位OS为9.2个月，而EP+atezolizumab为9.5个月（HR:1.52[1.05–2.19]，p=0.026）。12个月的OS分别为31%和42%。中位PFS分别为5.7个月和6.4个月（HR:1.53[1.06–2.22]，p=0.023）。在单变量分析中，生存率与年龄、性别和ECOG等已知预后变量之间没有关联。Megan Prictor1,2，Amelia Hyatt3,41健康数字化转型中心，墨尔本大学，维多利亚州，澳大利亚墨尔本2墨尔本法学院，墨尔本大学，澳大利亚墨尔本，VIC 3澳大利亚墨尔本大学Peter MacCallum肿瘤系4澳大利亚维多利亚州墨尔本癌症中心Peter MacCall勒姆健康服务研究与实施科学，理解、参与、对护理的满意度和护理质量。然而，在澳大利亚，目前缺乏有关当前咨询记录活动的数据。方法：一个由肿瘤学家和运动生理学家组成的多学科工作组为癌症患者开发了一种适当和可持续的运动计划途径。开发了一个简单的转诊表，该表易于访问，使参与者能够自我转诊，并允许临床转诊。吉普斯兰的运动生理学家通过参加癌症特定认证运动项目的课程，获得了提高技能的支持。该项目由Latrobe社区卫生服务中心的运动生理学家提供，并得到联合健康助理（AHA）和Morwell休闲中心（MLC）健身专业人员的支持，被认为对Latrobe山谷的癌症患者有重大益处，三家公司拒绝了。小组会议包括4至19名患者，在项目之后，8名患者继续使用休闲中心进行持续活动。锻炼小组的反馈绝大多数都是积极的。参与者能够满怀信心地进入休闲中心设施，因为他们已经了解健身团队，有助于锻炼的可持续性。结论：医疗保健服务和休闲中心之间的合作对于确保肿瘤患者在医疗保健服务之外的可持续锻炼计划是必要的。参与者重视医疗机构以外的医疗专业人员的支持。Angela Ives1、Christobel Saunders 2、Karen Taylor 3、Kathleen O’Connor3、Lesley Millar 11西澳大利亚大学医学院，西澳大利亚州珀斯2墨尔本大学，墨尔本3西澳大利亚州健康，珀斯3西澳大利亚背景：西澳大利亚癌症网络委托进行癌症患者体验调查，认识到患者的声音是健康可持续性的重要支柱。该项目旨在确定癌症护理中对患者重要的领域，通过确定医疗服务差距和患者在癌症旅程中体验的变化。这项工作是对UWA在基于价值的癌症护理方面的研究计划，即CIC癌症项目的补充。方法：采用All.Can国际患者体验调查。收集的数据反映了患者在诊断、护理和治疗方面的经验，以及癌症对生活质量的持续支持和经济影响。2019年，调查被邮寄给华盛顿州所有10348名18岁以上被诊断为癌症的人，并被张贴或在线完成。结果：共收到3238份（31.3%）调查，3182份通过邮件，56份在线。受访者在年龄、性别、癌症类型和地点方面具有代表性。研究结果的一个优势是所代表的癌症的广度，为不同的癌症旅程提供了重要的见解。接受私人治疗的受访者（1295人，40.0%）比接受公开治疗的受访者多（1123人，34.7%），742人（22.9%）同时接受了这两种治疗。最常见的癌症是前列腺癌（23.3%）、乳腺癌（19.1%）、黑色素瘤（11.5%）和结直肠癌（9.9%）。超过80%的受访者对他们的癌症经历感到满意。如果治疗发生在珀斯，与大都市受访者相比，农村和偏远地区的受访者有额外的费用，尤其是与经营双家庭和旅行有关的费用。年轻的受访者表示，他们的每一个护理领域都可以得到改善，可能是因为期望值更高。受访者强调，改进的机会包括改进沟通、高效及时的访问和支持。结论：这是首次在西澳大利亚进行癌症人群患者体验研究。研究结果将为未来癌症服务的规划和发展提供信息。建议定期进行进一步调查。Angela Ives1、Karen Taylor 2、Kathleen O’Connor2、Christobel Saunders31华盛顿大学，华盛顿州克劳利，澳大利亚2癌症网络，华盛顿州珀斯，澳大利亚3墨尔本大学，墨尔本，维多利亚，澳大利亚背景：华盛顿州癌症网络委托进行了一项癌症患者体验调查，认识到患者的声音是健康可持

{"title":"Poster Abstracts","authors":"","doi":"10.1111/ajco.14026","DOIUrl":"https://doi.org/10.1111/ajco.14026","url":null,"abstract":"Laura E Anderson1,2, Katelyn Collins1,3, Larry Myers1,3, Michael J Ireland3,4, Mariam Omar1, Allanah Drummond3, Leah Zajdlewicz1, Belinda Goodwin1,4,51Cancer Council Queensland, Fortitude Valley, Queensland, Australia2National Centre for Youth Substance Use Research, The University of Queensland, St Lucia, Queensland, Australia3School of Psychology and Wellbeing, University of Southern Queensland, Springfield, Queensland, Australia4Centre for Health Research, University of Southern Queensland, Springfield, Queensland, Australia5Melbourne School of Population and Global Health, University of Melbourne, Melbourne, Queensland, AustraliaAims: Population-wide cancer screening programs save lives through early cancer detection; however, many people do not participate. We aimed to understand decision formation and prompts to action for screening behaviours to inform interventions to increase bowel, breast and cervical cancer screening uptake.Methods: Cancer screeners (N = 962) were asked what made them decide to screen and what prompted them to act through an online survey. Content analysis was used to capture the frequency of common responses. Interrater reliability was high (κ = .96, %agree = 97%).Results: For breast and cervical screening, decisions were commonly based on ‘screening being routine’ (32.58% – breast, 35.19% – cervical) or ‘receiving a reminder’ (20.53% – breast, 13.07% – cervical), and common prompts were ‘receiving a reminder’ (40.68% – breast, 29.13% – cervical), ‘screening being routine’ (22.05% breast, 18.65% cervical). Participants reported deciding to screen for bowel cancer due to ‘arrival of home screening test kit’ (40.50%) or the ‘experience of loved one's cancer’ (13.57%) and were prompted by ‘arrival of home test kit’ (23.58%), ‘convenience’ (15.72%) and the ‘desire to “get it over with”’ (10.22%). Importantly, approximately 25% of participants gave the same response to both the decision and prompt question.Conclusions: Interventions should target reminders and messages that support screening as part of regular healthcare routine, particularly for breast and cervical cancer screening. For bowel cancer screening, messaging should encourage immediate use of bowel cancer screening kits upon arrival. The messaging inviting individuals to screening programs should be carefully considered, as it often coincides with both the decision to participate and prompts action.Shalmoli Bhattacharyya1, Sanchita Khurana1, Reena Sharma2, Bhavana Rai2, Rashmi Bagga31Biophysics, PGIMER, Chandigarh, India2Radiotherapy, PGIMER, Chandi","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14026","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68180145","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0

Oral Abstracts 口头摘要
IF 1.9 4区医学 Q3 Medicine
Asia-Pacific journal of clinical oncology
Pub Date : 2023-10-26 DOI: 10.1111/ajco.14025

Rhett Morton¹, Marcelo Nascimento², Penny Mackenzie¹, Kathryn Middleton³, Shaun McGrath³, Anna Kuchel¹, Danica Cossio⁴, Victoria Donoghue⁴, Karen Sanday⁵, Neal Rawson⁴, Euan Walpole^4,6, Andrea Garrett¹
¹Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia
²Gold Coast University Hospital, Gold Coast, Queensland, Australia
³Mater Hospital Brisbane, Brisbane, Queensland, Australia
⁴Cancer Alliance Queensland, Wooloongabba, Queensland, Australia
⁵Queensland Centre for Gynaecological Cancer, Brisbane, Queensland, Australia
⁶Princess Alexandra Hospital, Brisbane, Queensland, Australia
Aims: To understand the patterns of treatment for gynecological cancers (GC) across Queensland between 2012 and 2021 and look for areas of improvement.
Methods: The source of population data for this study is the Queensland Oncology Repository (QOR), which is a comprehensive clinical cancer database that links diagnostic information from the Queensland Cancer Register (QCR), with treatment data (radiation therapy, surgery, and intravenous systemic therapy), admissions data for both public and private hospitals, and patient outcome data.  Clinical data including FIGO stage and biomarkers was extracted from the Queensland Centre for Gynaecological Cancer database and linked to QOR.
Results:  A total of 11,909 Queensland women were diagnosed with GC between 2012 and 2021.  The most common diagnosis is endometrial (45%, n = 5378) followed by ovarian (29%, n = 3453) and then cervical (18%, n = 2127) with the three making up 92% of all GC.
Women with GC typically require a multidisciplinary approach to their care, including surgery, radiation therapy, and systemic therapy.  The overall treatment rate is high at 88% (n = 10,423/11,909).  73% of all GC diagnoses underwent resection with endometrial cancer having the highest resection rate of 84%. Radiation therapy treatment rates were highest for cervical cancer (47%), while systemic therapy rates were highest (70%) for ovarian cancer.
Small increases in the radiation therapy treatment rate between 2012 and 2016 and 2017 and 2021 were observed for endometrial (22%–26%) and vulval (29%–35%) cancers.
Survival for GC varies across the individual primary sites with endometrial cancer survival at 5 years 78% compared to ovarian at 44%.
Conclusion:  Accessing linked population-wide data enables active monitoring of care patterns for women with GC. This resource facilitates the extraction of valuable insights and evaluation of effective strategies and interventions to prevent, detect, diagnose, and treat GC. 
Tamara Butler

方法：使用的数据来自关联数据集，包括医疗保险福利计划、药物福利计划、维多利亚州乳腺筛查（BSV）、维多利亚州入院发作数据集、维多利亚州放射治疗最低数据集和维多利亚州癌症登记处（VCR）。从VCR中确定了2011年至2019年间被诊断患有侵袭性癌症的50岁至69岁的女性（n=20069）。与早期检测阶段一致被定义为通过BSV诊断或在诊断前3年至90天进行非BSV乳房X光检查。使用逻辑回归和Cox风险模型的风险比计算比值比。结果：20069年中，共有11517人（57%）符合筛查建议（45%通过BSV，12%通过非BSV乳房X光检查）。SES五分位数和偏远地区之间的一致性相似。在符合条件的队列中，诊断为1期的女性比例更高（63%比30%）。校正年龄后，对齐与诊断早期相关（OR=0.26，95%CI:0.25-.28）。接受保乳手术的女性比例更高（82%对61%），在根据年龄和分期进行调整后，其持续存在（OR:.59，95%CI:.55-.64）。调整年龄和分期后，符合早期检测阶段的患者的生存率有所提高（HR:.52，95%CI:.43-.64）结论：符合OCP的筛查建议与诊断为癌症的筛查年龄女性的更好结果相关。Zoe G Gibbs1,2，Caitlin I Fox-Harding1,2，Daniel A Galvão1,2，Dennis R Taafffe1,2，Rob U Newton1,21Edith Cowan University，Joondalup，WA，Australia2Exercise Medicine Research Institute，Joondarup，WA，澳大利亚目的：我们在一项为期12周、为期4个月的随机对照试验中检查了阻力运动负荷的操作，其中评估了高负荷（HL）或低负荷（LL）训练的有效性，以完善治疗乳腺癌相关淋巴水肿（BCRL）的运动处方。参与者和方法：BCRL幸存者（n=94，年龄22-84岁，平均54岁）被随机分配到常规护理（UC，n=31）、HL（n=31）或LL（n=32）运动组。每周两次的运动包括2-4组上半身和下半身阻力运动，HL从最大8次重复（RM）发展到5次重复，LL从最大18次重复发展到15次重复，再加上有氧训练（心率最大65%-80%时，15-25分钟）。在基线、12周和4个月的随访中评估淋巴相对体积（LRV）、肌肉功能和功能表现（反复坐椅子、400米步行）。统计分析包括ANOVA和ANCOVA。结果：73名参与者完成了研究。与UC相比，HL和LL在12周的干预中均降低了LRV（HL−8.6%，LL−7.8%；p=0.001），在4个月的随访中没有进一步的显著变化。两个运动组的肌肉力量都有所改善（p=0.001），UC没有变化（胸部按压：HL 4.7 kg，LL 3.8 kg；坐排：HL 9.7 kg，LL 4.9 kg；腿部伸展：HL 5.6 kg；LL 3.9 kg），HL和LL之间没有差异。HL（−36.2秒，p=.025）和LL（−18.9秒，p=.004）在400米步行中的表现也随着锻炼而改善，与LL（p=.020）相比，HL产生了显著的改善，结论：我们证明高负荷和低负荷抵抗运动对BCRL幸存者有效治疗淋巴水肿是可行的，并且在运动后4个月内身体和功能表现都有所改善。Yada Kanjanapan1,2，Wayne Anderson3，Mirka Smith3，Jenny Green3，Elizabeth Chalker3，Paul Craft1,21澳大利亚首都堪培拉堪培拉医院肿瘤医学部2澳大利亚国立大学堪培拉3澳大利亚首都堪培拉卫生局数据分析处，澳大利亚简介：在使用不同的合格标准分别使用阿匹昔单抗和核糖昔单抗的君主试验和NATALEE试验中，使用辅助CDK4/6抑制剂加强治疗提高了无病生存率。我们评估了癌症患者在澳大利亚人群中符合这些标准的比例及其结果。方法：对ACT癌症治疗组（1997年6月-2017年6月）的连续患者进行分析。符合君主E条件的患者具有&gt；=4+淋巴结（LN）或1-3+LN加肿瘤&gt；=5 cm或3级。NATALEE还包括LN阴性&gt；5厘米和2.1−5厘米的3级癌症。采用卡方检验对各组进行比较；Kaplan–Meier法估计生存率。结果：在3840例激素受体阳性HER2阴性癌症患者中，718例（18.7%）符合君主E标准；2024人（52.7%）符合NATALEE资格。符合君主E条件的患者更年轻（中位数为56岁对59岁，p＜0.001），绝经前患者比例更高（34%对。 22%；0.001）。接受化疗的符合条件的患者明显增多（81%对33%，p＜0.001）。符合条件的中位总生存期较短（61个月对105个月，HR 1.89，95%CI:1.60–2.22，p＜001）。符合NATALEE条件的患者更有可能在绝经前接受更高的化疗（66%对16%）。淋巴结阴性患者占符合NATALEE条件的队列的31%，而符合NATALE条件的LN阴性患者占26%。符合NATALEE条件的患者的生存率低于不符合条件的患者，中位数为78个月对106个月（HR 1.36，95%CI:1.16–1.59，p&lt；0.001）。在符合NATALE条件的患者中，65%（n=1306），即34%的研究人群不符合君主制。符合这两项研究标准的患者的生存率低于仅符合NATALEE标准的患者（中位数61个月vs.96个月，HR 1.78，95%CI:1.47-2.14，p&lt；0.001）。Antonia Pearson 1，2，Haryana Dhillon3，Jill Chen3，Janine Lombard4，5，6，Martha Hickey7，8，Belinda Kiely 9，10111新南威尔士州Frenchs Forest的Northhern Beaches医院，澳大利亚2悉尼大学，Camperdown，澳大利亚3医学心理学中心；基于证据的决策，悉尼大学理学院心理学院，澳大利亚坎珀敦4纽卡斯尔私立医院，澳大利亚纽卡斯尔5医学肿瘤学，Calvary Mater Newcastle，澳大利亚纽卡斯尔6纽卡斯尔大学，澳大利亚纽卡斯尔7墨尔本大学，墨尔本8妇产科；澳大利亚墨尔本皇家女子医院妇科9NHMRC临床试验中心，悉尼大学，澳大利亚坎珀敦10澳大利亚坎珀镇癌症治疗中心11澳大利亚康科德癌症中心康科德遣返综合医院康科德，澳大利亚目的：我们旨在提高对癌症（BC）女性泌尿生殖系统症状（GUS）的认知和体验的理解。方法：来自9家新南威尔士州癌症服务机构和癌症网络澳大利亚成员的肿瘤诊所参与者完成了一项调查，内容涉及GUS的类型和影响，以及对治疗方案的看法。结果：505名妇女完成了调查：平均年龄59岁（30-83岁）；52%目前性活跃；58%目前正在接受内分泌治疗；84%为早期BC。70%的受访者报告患有GUS，少数人报告因此改变（5%）或停止（4%）内分泌治疗。阴道干燥是最常见的症状（62%），其次是穿刺疼痛（41%）和瘙痒（33%）。只有38%的受访者回忆起他们的癌症医生曾警告过GUS可能是B

{"title":"Oral Abstracts","authors":"","doi":"10.1111/ajco.14025","DOIUrl":"https://doi.org/10.1111/ajco.14025","url":null,"abstract":"Rhett Morton1, Marcelo Nascimento2, Penny Mackenzie1, Kathryn Middleton3, Shaun McGrath3, Anna Kuchel1, Danica Cossio4, Victoria Donoghue4, Karen Sanday5, Neal Rawson4, Euan Walpole4,6, Andrea Garrett11Royal Brisbane and Women's Hospital, Brisbane, Queensland, Australia2Gold Coast University Hospital, Gold Coast, Queensland, Australia3Mater Hospital Brisbane, Brisbane, Queensland, Australia4Cancer Alliance Queensland, Wooloongabba, Queensland, Australia5Queensland Centre for Gynaecological Cancer, Brisbane, Queensland, Australia6Princess Alexandra Hospital, Brisbane, Queensland, AustraliaAims: To understand the patterns of treatment for gynecological cancers (GC) across Queensland between 2012 and 2021 and look for areas of improvement.Methods: The source of population data for this study is the Queensland Oncology Repository (QOR), which is a comprehensive clinical cancer database that links diagnostic information from the Queensland Cancer Register (QCR), with treatment data (radiation therapy, surgery, and intravenous systemic therapy), admissions data for both public and private hospitals, and patient outcome data.  Clinical data including FIGO stage and biomarkers was extracted from the Queensland Centre for Gynaecological Cancer database and linked to QOR.Results:  A total of 11,909 Queensland women were diagnosed with GC between 2012 and 2021.  The most common diagnosis is endometrial (45%, n = 5378) followed by ovarian (29%, n = 3453) and then cervical (18%, n = 2127) with the three making up 92% of all GC.Women with GC typically require a multidisciplinary approach to their care, including surgery, radiation therapy, and systemic therapy.  The overall treatment rate is high at 88% (n = 10,423/11,909).  73% of all GC diagnoses underwent resection with endometrial cancer having the highest resection rate of 84%. Radiation therapy treatment rates were highest for cervical cancer (47%), while systemic therapy rates were highest (70%) for ovarian cancer.Small increases in the radiation therapy treatment rate between 2012 and 2016 and 2017 and 2021 were observed for endometrial (22%–26%) and vulval (29%–35%) cancers.Survival for GC varies across the individual primary sites with endometrial cancer survival at 5 years 78% compared to ovarian at 44%.Conclusion:  Accessing linked population-wide data enables active monitoring of care patterns for women with GC. This resource facilitates the extraction of valuable insights and evaluation of effective strategies and interventions to prevent, detect, diagnose, and treat GC. Tamara Butler</sp","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14025","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"68180718","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0

COSA committees 什么委员会。
IF 1.9 4区医学 Q3 Medicine
Asia-Pacific journal of clinical oncology
Pub Date : 2023-10-26 DOI: 10.1111/ajco.14018

A/Professor Dion Forstner – President
Professor Sabe Sabesan – President Elect
Ms Sandie Angus
Professor Judy Bauer
Professor Tanya Buchanan
Clinical A/Professor Merran Findlay (commenced March 2023)
Mr Peter Hooker
Dr Malinda Itchins
Professor Michael Jefford
Professor Tim Price
A/Professor Christopher Steer
A/Professor Dion Forstner – President
Professor Sabe Sabesan – President Elect
Professor Fran Boyle AM – Immediate Past President
Professor Meera Agar – Geriatric Oncology
A/Professor Arun Azad – Urologic Oncology
Ms Kathy Bell – Consumer Representative
Dr David Chan – Neuroendocrine Tumours
Professor Raymond Chan – Cancer Survivorship
Dr Connie Diakos – Gastrointestinal Cancer
Dr Susan Fraser – Breast Cancer
Professor Gail Garvey – First Nations Representative
Dr Ashley Hopkins – Epidemiology
Dr Malinda Itchins – Lung Cancer
Dr Laura Kirsten – Psycho-Oncology
Dr Andrea Knox – Advanced Trainee Representative (resigned April 2023)
Ms Merran Findlay – Nutrition (resigned March 2023)
Dr Eng-Siew Koh – Neuro-Oncology
Dr Judith Lacey – Integrative Oncology
Dr Wei-Sen Lam – Regional and Rural
Ms Jenelle Loeliger – Nutrition (commenced April 2023)
A/Professor Alex Menzies – Melanoma and Skin Cancer (resigned March 2023)
Professor Linda Mileshkin – Gynaecological Cancer
Dr David Mizrahi – Exercise and Cancer
Dr Wayne Nicholls – Adolescent and Young Adult
Dr Sophie Nightingale – Surgical Oncology
Professor Jane Phillips – Palliative Care
Ms Marissa Ryan – Cancer Pharmacists (Co-Chair)
Dr Geeta Sandhu – Cancer Pharmacists (Co-Chair)
Professor Clare Scott AM – Rare Cancers
Professor Bernard Stewart AM – Cancer Prevention
Mr Adam Stoneley – Clinical Trials and Research Professionals
Mr Simon Troth – Cancer Genetics
Dr Paul Viray – Advanced Trainee Representative (commenced June 2023)
Distinguished Professor Patsy Yates AM – Cancer Care Coordination
Professor Desmond Yip – Global Oncology
Ms Leonie Young – Consumer Representative
Professor Nik Zeps – Cancer Biology
Ms Marie Malica – Chief Executive Officer
Australasian Gastro-Intestinal Trials Group – Professor Tim Price
Australasian Leukaemia & Lymphoma Group – Professor Judith Trotman
Australia & New Zealand Sarcoma Association – Professor Angela Hong
Australian and New Zealand Children's Haematology/Oncology Group – Dr Nick Gottardo
Australia New Zealand Gynaecology Oncology Group – Professor Clare Scott AM
Australia and New Zealand Head & Neck Cancer Society – Dr Tsien Fua
Australia and New Zealand Urogenital & Prostate Cancer Trials Group – Professor Ian Davis
Breast Cancer Trials – Professor Sunil Lakhani
Cancer

A/Dion Forstner教授-主席Sabe Sabesan教授-候任主席Sandie Angus女士Judy Bauer教授Tanya Buchanan教授临床A/Merran Findlay教授（2023年3月开始）Peter Hooker先生Malinda Itchins博士Michael Jefford教授Tim PriceA/Christopher Steer教授A/Dion Fosstner教授Boyle AM–前任主席Meera Agar教授–老年肿瘤A/Arun Azad教授–泌尿肿瘤Kathy Bell女士–消费者代表David Chan博士–神经内分泌肿瘤Raymond Chan教授–癌症幸存者Connie Diakos博士–胃肠道癌症Susan Fraser博士–乳腺癌Gail Garvey教授–第一民族代表Ashley Hopkins博士–流行病学Malinda Itchins博士–肺癌Laura Kirsten博士–精神肿瘤学Andrea Knox博士–高级实习生代表（2023年4月辞职）Merran Findlay女士–营养学（2023月辞职）Eng Siew Koh博士–神经肿瘤学Judith Lacey博士–综合肿瘤学Wei Sen Lam博士–区域和RuralJenelle Loeliger女士–营养学Menzies–黑色素瘤和皮肤癌症（2023年3月辞职）Linda Mileshkin教授–妇科癌症David Mizrahi博士–运动和癌症Wayne Nicholls博士–青少年和青少年Sophie Nightingale博士–外科肿瘤Jane Phillips教授–姑息治疗Marissa Ryan女士–癌症药剂师（Co-Chair）Geeta Sandhu博士–癌症药剂师（Co-C hair）Clare教授Scott AM–罕见癌症Bernard Stewart AM教授–癌症预防Adam Stonley先生–临床试验和研究专业Simon Troth先生–癌症基因Paul Viray先生–高级实习生代表（2023年6月开始）尊敬的Patsy Yates AM教授–癌症护理协调Desmond Yip教授–全球肿瘤Leonie Young女士–消费者代表Nik Zeps教授——癌症生物学Marie Malica女士——澳大利亚胃肠道临床试验小组首席执行官——Tim Price教授——澳大利亚白血病和白血病；淋巴瘤小组-Judith TrotmanAustralia&；新西兰肉瘤协会-Angela Hong教授澳大利亚和新西兰儿童血液学/肿瘤组-Nick Gottardo博士澳大利亚和新西兰妇科肿瘤组-Clare Scott AMAustralia教授和新西兰负责人；颈部癌症协会-Tsien Fua博士澳大利亚和新西兰泌尿生殖器官和；前列腺癌症试验组——Ian Davis教授乳腺癌症试验——Sunil Lakhani教授澳大利亚癌症护士协会——加布里埃尔•维加尔女士（2023年3月辞职）澳大利亚癌症护士协会——A/Deborah Kirk教授（2023月开始）癌症症状试验组——Rayan Saleh Moussa博士神经内科合作试验组——Eng-Siew Koh博士放射肿瘤–Gerard Adams博士（2023年2月开始）澳大利亚人类遗传学学会–Simon Troth先生澳大利亚医学肿瘤小组–Deme Karikios博士（2022年8月辞职）澳大利亚医学肿瘤组–A/Melissa Eastgate教授（2023月开始）黑色素瘤和皮肤癌症试验–Mark Shackleton教授澳大利亚-新西兰癌症社会工作–Kim Hobbs女士初级保健合作癌症临床试验小组–Carolyn Ee博士精神疾病合作研究小组–Joanne Shaw博士澳大利亚皇家病理学家学院–Kenneth Lee博士澳大利亚胸肿瘤小组–Michael Millward TROG教授癌症研究–Puma Sundaresan博士Belinda Yeo博士–召集人Marliese Alexander女士Kathy Bell女士Nicole KinnaneMsSuzanne Komp Chi Hao LaA/Brigid Lynch教授Linda MileshkinAndrew MurnaneDr Sophie NightingaleA/Lesley Stafford教授Belinda Steer博士Paul Viray女士Fran Doughton女士–COSA行政部门Marie Malica女士–COSA首席执行官Marie Malika女士–首席执行官Rhonda DeSouzaMaryanne Doherty女士Fran Doghton女士Roger Falconer Flint女士Rosannah女士Girlesstone博士Hayley Griffin女士Gillian Mackay女士Kristen Allen女士–项目办公室Fiona Chambers女士–高级项目办公室Chad Murphy先生–赞助总监Hannah Pickford女士–重大项目总监Mike Pickford先生–执行董事Jordyn Trolove女士–高级工程经理

{"title":"COSA committees","authors":"","doi":"10.1111/ajco.14018","DOIUrl":"10.1111/ajco.14018","url":null,"abstract":"\u0000 \u0000 A/Professor Dion Forstner – PresidentProfessor Sabe Sabesan – President ElectMs Sandie AngusProfessor Judy BauerProfessor Tanya BuchananClinical A/Professor Merran Findlay (commenced March 2023)Mr Peter HookerDr Malinda ItchinsProfessor Michael JeffordProfessor Tim PriceA/Professor Christopher SteerA/Professor Dion Forstner – PresidentProfessor Sabe Sabesan – President ElectProfessor Fran Boyle AM – Immediate Past PresidentProfessor Meera Agar – Geriatric OncologyA/Professor Arun Azad – Urologic OncologyMs Kathy Bell – Consumer RepresentativeDr David Chan – Neuroendocrine TumoursProfessor Raymond Chan – Cancer SurvivorshipDr Connie Diakos – Gastrointestinal CancerDr Susan Fraser – Breast CancerProfessor Gail Garvey – First Nations RepresentativeDr Ashley Hopkins – EpidemiologyDr Malinda Itchins – Lung CancerDr Laura Kirsten – Psycho-OncologyDr Andrea Knox – Advanced Trainee Representative (resigned April 2023)Ms Merran Findlay – Nutrition (resigned March 2023)Dr Eng-Siew Koh – Neuro-OncologyDr Judith Lacey – Integrative OncologyDr Wei-Sen Lam – Regional and RuralMs Jenelle Loeliger – Nutrition (commenced April 2023)A/Professor Alex Menzies – Melanoma and Skin Cancer (resigned March 2023)Professor Linda Mileshkin – Gynaecological CancerDr David Mizrahi – Exercise and CancerDr Wayne Nicholls – Adolescent and Young AdultDr Sophie Nightingale – Surgical OncologyProfessor Jane Phillips – Palliative CareMs Marissa Ryan – Cancer Pharmacists (Co-Chair)Dr Geeta Sandhu – Cancer Pharmacists (Co-Chair)Professor Clare Scott AM – Rare CancersProfessor Bernard Stewart AM – Cancer PreventionMr Adam Stoneley – Clinical Trials and Research ProfessionalsMr Simon Troth – Cancer GeneticsDr Paul Viray – Advanced Trainee Representative (commenced June 2023)Distinguished Professor Patsy Yates AM – Cancer Care CoordinationProfessor Desmond Yip – Global OncologyMs Leonie Young – Consumer RepresentativeProfessor Nik Zeps – Cancer BiologyMs Marie Malica – Chief Executive OfficerAustralasian Gastro-Intestinal Trials Group – Professor Tim PriceAustralasian Leukaemia & Lymphoma Group – Professor Judith TrotmanAustralia & New Zealand Sarcoma Association – Professor Angela HongAustralian and New Zealand Children's Haematology/Oncology Group – Dr Nick GottardoAustralia New Zealand Gynaecology Oncology Group – Professor Clare Scott AMAustralia and New Zealand Head & Neck Cancer Society – Dr Tsien FuaAustralia and New Zealand Urogenital & Prostate Cancer Trials Group – Professor Ian DavisBreast Cancer Trials – Professor Sunil LakhaniCancer","PeriodicalId":8633,"journal":{"name":"Asia-Pacific journal of clinical oncology","volume":null,"pages":null},"PeriodicalIF":1.9,"publicationDate":"2023-10-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ajco.14018","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"54227510","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0

首页上一页

2

3

4

5

6

7

8

9

...

10

下一页尾页

类型

全部化学•材料生命科学医学物理工程技术环境•农林材料科学地球科学法学管理学化学环境科学与生态学计算机科学教育学经济学农林科学人文科学生物学数学物理与天体物理心理学综合性期刊其他工业工程理学历史学农学文学信息工程

数据库

全部 ACS Publications Elsevier ieeexplore Springer The Royal Society of Chemistry Wiley

期刊

Asia-Pacific journal of clinical oncology

全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
﹀